1. Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021;22:757–773.

2. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022;603:679–686.

3. Willett BJ, Grove J, MacLean OA, et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol 2022;7:1161–1179.

4. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021;398:2126–2128.

5. Chin ET, Leidner D, Lamson L, et al. Protection against omicron from vaccination and previous infection in a prison system. N Engl J Med 2022;387:1770–1782.

6. Chalkias S, Whatley JL, Eder F, et al. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results. Nat Med 2023;29:2325–2333.

7. Souza MS, Farias JP, Andreata-Santos R, et al. Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: insights to the future. J Med Virol 2024;96:e29416.

8. Choi SK, Kim S, Ko M, et al. Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea. Osong Public Health Res Perspect 2024;15:542–549.

9. Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022–April 2023. MMWR Morb Mortal Wkly Rep 2023;72:579–588.

10. Kim RK, Choe YJ, Jang EJ, et al. Comparative effectiveness of COVID-19 bivalent versus monovalent mRNA vaccines in the early stage of bivalent vaccination in Korea: October 2022 to January 2023. J Korean Med Sci 2023;38:e396.

11. Mimura W, Ishiguro C, Terada-Hirashima J, et al. Bivalent vaccine effectiveness among adults aged ≥65 years during the BA.5-predominant period in Japan: the VENUS study. Open Forum Infect Dis 2023;10:ofad475.

12. Lin DY, Xu Y, Gu Y, et al. Effectiveness of bivalent boosters against severe omicron infection. N Engl J Med 2023;388:764–766.

13. Trieu MC, Reynaldi A, Lee WS, et al. Bivalent mRNA booster vaccination recalls cellular and antibody immunity against antigenically divergent SARS-CoV-2 spike antigens. NPJ Vaccines 2025;10:74.

14. Tan NH, Geers D, Sablerolles RSG, et al. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Lancet Infect Dis 2023;23:901–913.

15. Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against Covid-19. N Engl J Med 2022;387:1279–1291.

16. Khairat S, Zou B, Adler-Milstein J. Factors and reasons associated with low COVID-19 vaccine uptake among highly hesitant communities in the US. Am J Infect Control 2022;50:262–267.

17. Wrenn JO, Pakala SB, Vestal G, et al. COVID-19 severity from Omicron and Delta SARS-CoV-2 variants. Influenza Other Respir Viruses 2022;16:832–836.

18. Wiemken TL, Khan F, Puzniak L, et al. Seasonal trends in COVID-19 cases, hospitalizations, and mortality in the United States and Europe. Sci Rep 2023;13:3886.

19. Townsend JP, Hassler HB, Lamb AD, et al. Seasonality of endemic COVID-19. mBio 2023;14:e0142623.

20. Sun H, Xu J, Zhang G, et al. Developing pseudovirus-based neutralization assay against omicron-included SARS-CoV-2 variants. Viruses 2022;14:1332.

21. Zou J, Kurhade C, Patel S, et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine. N Engl J Med 2023;388:854–857.

22. Miller J, Hachmann NP, Collier AY, et al. Substantial neutralization escape by SARS-CoV-2 omicron variants BQ.1.1 and XBB.1. N Engl J Med 2023;388:662–664.

23. Urschel R, Bronder S, Klemis V, et al. SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals. Nat Commun 2024;15:3077.

24. Nham E, Kim J, Lee J, et al. Low neutralizing activities to the omicron subvariants BN.1 and XBB.1.5 of sera from the individuals vaccinated with a BA.4/5-containing bivalent mRNA vaccine. Immune Netw 2023;23:e43.

25. Shigayeva A, Kandel C, Farooqi L, et al. Early COVID-19 and protection from Omicron in a highly vaccinated population in Ontario, Canada: a matched prospective cohort study. BMC Infect Dis 2025;25:194.

26. Walmsley S, Nabipoor M, Qi F, et al. Declining levels of neutralizing antibodies to SARS-CoV-2 Omicron variants are enhanced by hybrid immunity and Original/Omicron bivalent vaccination. Vaccines (Basel) 2024;12:564.

27. Cheung AKL, Lu Y, Zhu Y, et al. Consistent neutralization of circulating omicron sub-variants by hybrid immunity up to 6 months after booster vaccination. J Med Virol 2023;95:e28694.

28. Naveed Siddiqui A, Musharaf I, Gulumbe BH. The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health. Ther Adv Infect Dis 2025;12:20499361251314763.

29. Eshraghi R, Bahrami A, Karimi Houyeh M, Nasr Azadani M. JN.1 and the ongoing battle: unpacking the characteristics of a new dominant COVID-19 variant. Pathog Glob Health 2024;118:453–458.

30. Happle C, Hoffmann M, Kempf A, et al. Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination. Lancet Infect Dis 2024;24:e674–e676.

31. Uriu K, Kaku Y, Kihara M, Sato K, Genotype to Phenotype Japan (G2P-Japan) Consortium. Antiviral humoral immunity against SARS-CoV-2 omicron JN.1 subvariants induced by JN.1 recombinant protein vaccine. Vaccine 2025;54:127129.